Apoptosis
Apoptosis, also known as programmed cell death, is rigorously controlled process of cell death that leads to phagocytosis of unwanted cell. It is triggered after sufficient cellular damage and activated through extrinsic or intrinsic pathways. The intrinsic pathway is mainly occurs via release of cytochrome c from the mitochondria and regulates mitochondrial outer membrane permeabilization by Bcl-2 family proteins. The extrinsic pathway is induced by ligand binding to death receptor, such as Fas, TNFαR, DR3, DR4, and DR5. Caspases then cleave target proteins and nuclear lamins to promote DNA degradation, resulting apoptotic cells undergo phagocytosis. In addition, p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some Inhibitors of apoptosis proteins (IAPs), such as XIAP/BIRC4 and Bruce/BIRC6, can block casapse activity through direct binding, while other IAPs, such as cIAP1/BIRC2, cIAP2/BIRC3, act as ubiquitin ligases that target caspases for ubiquitin-mediated degradation. Apoptosis is essential for growth, development and aging in multicellular organisms. Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases, including cancer.
-
BA8843 CTA056Summary: CTA056 is an (IL-2 inducible T cell kinase) inhibitor. - BA8846 c-Fms-IN-12Summary: c-Fms-IN-12 is an inhibitor that also inhibits.
- BA8882 ABN401Summary: ABN401 is a potent and selective competitive inhibitor of ATP.
- BA8943 PP58Summary: Pyrido[2,3-d]pyrimidine compounds.
- BA8978 AVJ16Summary: AVJ16, a cancer cell migration inhibitor targeting insulin-like growth factor 2 mRNA-binding protein, inhibits the migration of H1299 cells highly expressing endogenous IGF2BP1.
- BA8984 SoquelitinibSummary: Soquelitinib (CPI-818) is a highly selective covalent inhibitor.
- BA8989 ZeteletinibSummary: Zeteletinib (BOS-172738; DS-5010) is an orally effective, selective kinase inhibitor with nanomolar potency against and >300-fold selectivity for VEGFR2.
- BA8996 BT-13Summary: BT-13 is a potent, selective agonist (acting independently of GDNF ligands).
- BA8998 VepafestinibSummary: An inhibitor.
- BA9001 NSC194598Summary: NSC194598 is a p53 DNA binding inhibitor that inhibits p53 sequence-specific DNA binding in vitro and in vivo at values of 180 nM and 2-40 μM, respectively.